DOSE ESCALATION AND THE SAFETY OF CELECOXIB, IBUPROFEN, AND NAPROXEN: ANALYSIS OF THE PRECISION TRIAL

Autor:	Mingyuan Shao, A M Lincoff, Kathy Wolski, Grant W. Reed, Mouin Abdallah, Neville Yeomans, Peter Libby, Thomas F. Luscher, Steven E. Nissen, Lisa Wisniewski, Elaine Husni, David Y. Graham, Jeffrey Borer, Venuy Menon, Daniel H. Solomon
Rok vydání:	2018
Předmět:	musculoskeletal diseases Drug Naproxen medicine.medical_specialty business.industry organic chemicals media_common.quotation_subject Urology Arthritis Ibuprofen medicine.disease Celecoxib Dose escalation Medicine lipids (amino acids peptides and proteins) heterocyclic compounds In patient skin and connective tissue diseases Cardiology and Cardiovascular Medicine business medicine.drug media_common
Zdroj:	Journal of the American College of Cardiology. 71:A85
ISSN:	0735-1097
DOI:	10.1016/s0735-1097(18)30626-0
Popis:	The PRECISION trial demonstrated the non-inferiority of celecoxib to ibuprofen or naproxen for cardiovascular (CV) safety in patients with arthritis. A comparison of the overall safety of each agent stratified by drug dose has yet to be reported. Patients were randomized to lower-dose celecoxib 100
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::3ea84435c62a3f1ba10fd594c76d36a4 https://doi.org/10.1016/s0735-1097(18)30626-0 Zobrazit plný text záznamu